The receptor protein tyrosine phosphatase B (RPTPB) is a functional biomarker for several solid tumor types. RPTPB expression is largely restricted to the central nervous system and overexpressed primarily in astrocytic tumors. RPTPB is known to facilitate tumor cell adhesion and migration through interactions with extracellular matrix components and the growth factor pleiotrophin. Here, we show that RPTPB is expressed in a variety of solid tumor types with low expression in normal tissue. To assess RPTPB as a potential target for treatment of glioblastoma and other cancers, antibodies directed to RPTPB have been developed and profiled in vitro and in vivo. The recombinant extracellular domain of human short RPTPB was used to immunize mice and generate monoclonal antibodies that selectively recognize RPTPB and bind to the antigen with low nanomolar affinities. Moreover, these antibodies recognized the target on living tumor cells as measured by flow cytometry. These antibodies killed glioma cells in vitro when coupled to the cytotoxin saporin either directly or via a secondary antibody. Finally, in vivo studies showed that an anti-RPTPB immunotoxin (7E4B11-SAP) could significantly delay human U87 glioma tumors in a mouse xenograft model. Unconjugated 7E4B11 provides a modest but statistically significant tumor growth delay when delivered systemically in mice bearing U87 glioma tumors. (Cancer Res 2006; 66(4): 2271-8) 
Introduction
There are currently >500 new oncology drugs in clinical trials. This reflects the huge medical need and intense competition for innovative drugs to novel targets. Cell surface receptors are prime targets of therapy due to the fact that they often play vital roles in tumor biology and are amenable to both small molecule and monoclonal antibody (mAb) drugs. Receptors that are overexpressed or display abnormal signaling often distinguish a tumor cell from normal cells. However, the pharmacologic targeting of receptors is often complicated by the reality that some normal tissues express the cancer target and cause unwanted organ uptake or dangerous side effects. Therefore, the search for a uniquely tumor-specific target goes on. Despite this hurdle, there are several instances of successful strategies to target receptor tyrosine kinases (RTK), these include Herceptin (Genentech, South San Francisco, CA) and Cetuximab (Imclone Systems, New York, NY), antibodies to the epidermal growth factor receptor (EGFR) family of RTKs (1) . Few examples exist of the successful targeting of receptor protein tyrosine phosphatases (RPTP) by either small molecule or antibody-based therapeutics.
One such promising RPTP target is RPTPh, a protein that is overexpressed in astroctyomas (2) (3) (4) . In astroctyomas, increased expression levels of RPTPh correlate with a poor clinical prognosis (3) . RPTPh has a shown role in the migration and adhesion of tumor cells, and one of its primary ligands, pleiotrophin, is known to enhance tumor growth and angiogenesis (2, (5) (6) (7) . Until recently, very little was known regarding the intracellular signaling of RPTPh. Reports indicate that pleiotrophin can bind and inactivate RPTPh and thereby lead to increased tyrosine phosphorylation of h-catenin and Fyn (8, 9) . The extracellular domain of RPTPh has three characterized domains: a carbonic anhydrase, fibronectin III, and glycine-serine rich region (10) (11) (12) (13) . These regions differentially interact with various cell adhesion molecules, such as NgCAM, Contactin, and tenascin C, to facilitate cell attachment, repulsion, and signaling (14, 15) . Several splice variants of RPTPh have been described; these include the soluble matrix protein Phosphacan and long and short receptor forms (10, 11, 16) . The short receptor form lacks the 806-amino-acid, glycine-rich domain in the extracellular portion of the receptor. This truncation produces a receptor with a unique junction and a modified ligand-binding profile (4, 17) . Both long and short RPTPh are expressed in glioma tumor tissue (4) .
Antibody targeting of RPTPh is a promising approach for the treatment of cancer. RPTPh tissue expression is largely central nervous system (CNS) and developmentally restricted (12, 16, 18) . It has a shown role in tumor biology and is amenable to therapeutic targeting. The present study describes the generation and characterization of murine antibodies to RPTPh. The expression profile of RPTPh in both normal and tumor tissue (other than brain tumors) is described. We also detail the efficacy of antiRPTPh antibodies in both cell-based and in vivo tumor studies.
Materials and Methods
Materials. Human U87 (American Type Culture Collection, Manassas, VA) cells were cultured in DMEM supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) and 100 units/mL penicillin/streptomycin. Mouse mAbs against the COOH terminus of RPTPh were obtained from BD Transduction Labs (Franklin Lakes, NJ). Direct immunotoxin conjugates MAB-ZAP, IgG-SAP, DAT-SAP, 7A9B4-SAP, and 7E4B11-SAP were purchased (or created in the case of 7A9B4-SAP and 7E4B11-SAP) from Advanced Targeting Systems (San Diego, CA).
Mouse mAbs. Custom mouse mAbs were generated to the extracellular domain of recombinant human RPTPh short form. The extracellular domain for short RPTPh (residues 26-774), including the unique splice junction, was expressed with a COOH terminus 6Â His tag using baculovirus. The protein was purified from the media with two chromatography steps: immobilized metal affinity (Ni 2+ -NTA FF, Qiagen, Valencia, CA) followed by anion exchange (Q Sepharose FF, GE Healthcare, Pittsburgh, PA; ref. 4) . Mouse hybridomas were generated by Anaspec (San Jose, CA) using BALB/c mice with the protein immunogen in Freund's adjuvant. Spleen cells from immunized mice were fused with a mouse myeloma cell line. Supernatants were screened by ELISA using the RPTPh protein immunogen and isotyped, and RPTPh-specific IgG producing hybridomas were expanded, subcloned, and cultured. Promising hybridoma lines were grown, and the antibodies were purified from culture media using Protein A/G Montage Purification columns (Millipore, Billerica, MA).
Immunohistochemistry. Tissue MicroArray slides were used to study the expression RPTPh. Slides were placed on a heat block at 45jC for 4 to 6 hours and dewaxed using EZ-DeWax solution (Biogenex, San Ramon, CA). Slides were then placed in a bath containing Target Retrieval Solution (Innogenex) and simmered for 15 minutes in a microwave. Slides were stained with either the COOH terminus RPTPh antibody (Transduction Labs) or the custom made RPTPh mouse mAbs (Anaspec). The slides were processed using anti-mouse immunohistochemistry kits with 3,3V -diaminobenzidine colorimetric end-point detection and hematoxylin counterstain (Innogenex).
ELISA. To determine the specificity of antibody containing hybridoma supernatants and purified antibody preparations, 96-well Maxisorp plates (Nalgene, Rochester, NY) were coated in 0.5 mmol/L sodium bicarbonate solution containing 1 Ag/mL antigen for 1 hour at room temperature. The plates were then washed with PBS and blocked with bovine serum albumin for 1 hour. Antibodies were added to triplicate wells for 1 hour and then washed thrice with PBS containing 0.1% Tween 20 to remove unbound or nonspecific proteins. The anti-mouse IgG-horseradish peroxidase detection antibody was then added for 1 hour before the final washes in PBS containing 0.1% Tween 20. The immune complex was incubated briefly with TMB substrate (Sigma-Aldrich, St. Louis, MO) and stopped with 0.1 N HCl, and absorbance was detected at 490 nm on a plate reader. Triplicate experiments were done, and error bars represent SDs.
Affinity measurements/surface plasmon resonance. Biacore uses a sensor chip technology for monitoring interaction between two or more molecules in real time, without the use of labels. These studies were undertaken by Biacore contract services. The antibodies were captured on the sensor via anti-mouse IgG preimmobilized on the chip surface. The running buffer was HBSEP [50 mmol/L HEPES (pH 7.4), 150 mmol/L NaCl, 3 mmol/L EDTA, and 0.005% Surfactant P-20], and the analysis temperature was 25jC. The recombinant human short RPTPh was injected, using an automated method, up to 10 minutes at flow rates ranging from 10 to 50 AL/min. Binding data was fit to a 1:1 binding model using Biacore software (BIAevaluation v 4.1) to obtain the kinetic and affinity constants.
Antibody-mediated internalization assay. U87 cells were plated at 3,000 per well (30,000/mL) onto black-walled 96-well plates (BD, Franklin Lakes, NJ) and incubated overnight at 37jC in 5% CO 2 . The cells were treated with 200 ng/well primary antibody prepared in Opti-MEM (Life Technologies). The antibody treatments include the RPTPh ectodomain antibodies and control IgG. The cells were processed and stained with antiRPTPh endodomain mAb (Transduction Labs) and detected with antimouse Alexa 488 secondary antibody. The cells were imaged using an ArrayScan platform using Zeiss optics and Cellomics imaging algorithms. The punctuate nature of the staining indicates receptor-antibody internalization. Images representative of triplicate experiments are presented.
Colony formation in soft agar. To test the effect of 7E4B11 on colony formation, we used a cell transformation detection assay kit from Chemicon (Temecula, CA). Briefly, 24-well plates were prepared with 0.8% base agar in cell culture media (DMEM, 10% fetal bovine serum, 1% penicillin/ streptomycin). U87 cells were harvested and mixed at 4,000 per well in 0.4% top agar solution in cell culture media. Medium containing 20 Ag/mL IgG1 (Cymbus Biotechnology, Eastleigh, NH), 20 Ag/mL EGFR-528 (Santa Cruz Biotechnology, Santa Cruz, CA; ref. 19) , or 20 Ag/mL 7E4B11 was added in triplicate to the appropriate wells. The cells were incubated for 21 days at 37jC in 5% CO 2 with medium treatment changes every 3 to 4 days. At that time, colonies were stained and visualized using light microscopy. Triplicate experiments were done, and representative images were shown.
Immunotoxin-directed cell cytotoxicity. To evaluate if our RPTPh mouse antibodies can act as an immunotoxin, we tested indirect and direct immunotoxin-mediated cell cytotoxicity assays. For indirect immunotoxin assay, U87 cells were plated at 3,000 per well (30,000/mL) onto white-walled, 96-well plates (BD Falcon) and incubated overnight at 37jC in 5% CO 2 . The cells were treated with 200 ng/well primary antibody prepared in Opti-MEM (Life Technologies). The antibody treatments include the RPTPh antibodies as well as EGFR-528 (Santa Cruz Biotechnology; ref. 19 ), CD71 (Transduction Labs), and IgG1 (Cymbus Biotechnology). Half of the test wells ( four of eight) were subsequently treated with saporin-conjugated secondary antibody (MAB-ZAP) at 200 ng/well. The cells were then incubated for 3 days 37jC in 5% CO 2 . At that time, the number of viable cells was assessed using the luminescence-based detection reagent Cell Titer Glo (Promega, Madison, WI) and read on a luminometer. For direct immunotoxinmediated cell cytotoxicity assay, U87 cells were prepared the same as above but treated directly with the saporin toxin-conjugated antibodies IgG-SAP, DAT-SAP, 7A9B4-SAP, and 7E4B11-SAP (Advanced Targeting Systems). Triplicate experiments were done, and error bars represent SDs.
Tumor xenografts. Female athymic nude mice were 11 to 12 weeks old on day 1 of the study. The U87 glioblastoma line used for this study was maintained in athymic nude mice. A tumor fragment (1 mm 
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RPTPB antigen expression and immunization.
To provide the best source material for therapeutic antibody development, we subcloned the entire extracellular domain of short RPTPh into baculovirus expression vector. This construct has a polyhistidine tag introduced into the COOH terminus of the extracellular domain. The protein expressed from the baculovirus constructs was purified using conventional Nickel affinity column and other available methods to obtain the highest purity proteins (Fig. 1A) .
The short RPTPh antigen was tested for the ability to bind pleiotrophin and modulate cell adhesion (data not shown; ref. 4). Short RPTPh protein has a domain structure very similar to Phosphacan, an extracellular matrix proteoglycan with antiadhesive properties. In fact, short RPTPh and Phosphacan have comparable anti-adhesive abilities when tested in cell-based assays (4) . These studies indicate that the short RPTPh antigen used for immunization has retained structural and functional characteristics that may enhance the chances of generating functional antibodies.
Specificity and binding of RPTPB antibodies. Antibodies to RPTPh were screened by ELISA to determine specificity. In the ELISA experiment, a panel of purified antibodies was tested for binding to recombinant short RPTPh extracellular domain protein antigen (short RPTPh-ECD, black columns) or a unrelated but similarly expressed and purified control antigen, (NR-ECD, gray columns). The control protein used for this experiment is called GPR56 (20) and is a similarly glycosylated protein produced recombinately in a fashion nearly identical to RPTPh antigen. In this example, four of the five RPTPh antibodies tested gave a robust and specific signal for short RPTPh-ECD and did not recognize GPR56 (Fig. 1B) . In addition, we tested the ability of the antibodies to cross react with rat chondroitin sulfate proteoglycan mix that includes Phosphacan. Phosphacan is essentially the extracellular domain of RPTPh. Our lead antibodies did not significantly cross react with rat Phosphacan, indicating species selectivity (data not shown). The hybridomas corresponding to three of the four positive antibodies were selected and used for further study.
To measure binding of RPTPh antibodies to native epitopes, we used flow cytometry. Live human U87 glioma cells were incubated with the three lead candidate antibodies and detected using antimouse IgG-Alexa 488. Live cells were gated from dead cells (stained with propidium iodide) and measured for RPTPh-specific signal intensity (Fig. 1C ). An IgG1 isotype control (top) was compared with the three lead candidate RPTPh antibodies 1B9G4, 7A9B5, and 7E4B11. All three lead candidate RPTPh antibodies bind native epitope with a similar profile as indicated by the shift in fluorescence intensity peak. Figure 1 . Antigen production and antibody selectivity. A, the protein encoding the extracellular domain of short RPTPh was purified from the media with two chromatography steps. Immobilized metal affinity (Ni 2+ -NTA FF) followed by anion exchange (Q Sepharose FF). Arrow, recombinant human short RPTPh in its purified form. This material was used to immunize mice and for screening purposes. B, a subset of RPTPh antibodies generated from the immunization of mice with short RPTPh were tested by ELISA for selectivity to either recombinant short RPTPh (black columns ) or a nonspecific control protein (gray columns ). An IgG1-negative control isotype was included as a reference. Bars, SD. C, flow cytometry analysis of RPTPh antibody binding to live U87 glioma cells. Human U87 glioma cells were stained with control IgG1, 1B9G4, 7A9B5, or 7E4B11 as indicated and detected with a fluorescent secondary antibody. Live cells were gated from dead cells and the fluorescent intensity of the cell population measured using flow cytometry. D, immunohistochemistry analysis of normal and tumor tissue for RPTPh expression. Normal colon (i) had modest expression in some duct cells, whereas colon adenocarcinoma (ii ) was positive for RPTPh. Normal breast (iii ) had low expression in some duct cells, whereas invasive ductal carcinoma of the breast stained intensely for RPTPh. Normal lung (v ) did not stain for RPTPh, but lung adenocarcinoma displayed strong RPTPh immunoreactivity. Normal skin (vii ) did not stain with RPTPh, but melanoma (viii) was immunoreactive. Representative of the pattern of staining multiple tissue sections using COOH terminus-specific RPTPh antibody (Transduction Labs).
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To determine the affinity of each lead candidate antibody for the RPTPh antigen, we undertook surface plasmon resonance measurements using BIAcore technology. Each of the antigens and antibodies were initially tested to determine the binding specificity, antibody capture levels, and chip surface regeneration. Once the proper binding conditions were achieved, a concentration series of each antigen was injected over their respective antibody surfaces using an automated method. Regeneration solution was used to remove the antigen from the amine coupled antibody surface or the antibody/antigen from the captured surface. Binding data were fit to a 1:1 binding model using BIAcore software (BIAevaluation v4.1) to obtain the kinetic and affinity constants ( Table 1 ). All three lead candidate antibodies had similar low nmol/L affinities
RPTPB expression in normal and tumor tissue. There are a few published reports of RPTPh overexpression in human carcinomas, including astrocytoma and melanoma, but little else is known about RPTPh expression in peripheral tissues and tumors (21, 22) . We and others have studied the expression of RPTPh in high-grade astrocytomas (2-4). In our current work, we examined the expression of RPTPh in various tumor types (Table 2 ; Fig. 1D ).
Using an antibody to the COOH terminus of RPTPh, we surveyed several tumor types that revealed RPTPh overexpression (Table 2) . Consistent with published reports, RPTPh is overexpressed in melanomas (21) . Lung, colon, breast, and prostate carcinomas also stood out as having a significant number of tumor samples with RPTPh overexpression versus control tissue. Other tumor types, such as transitional carcinoma of the bladder and squamous cell carcinomas of the oral cavity and pharynx, were noteworthy. In addition, lymphoma also indicated up-regulation of RPTPh. A representative subset of the abovementioned cancers is presented in Fig. 1D , with matched normal controls. RPTPh is expressed most consistently in colon, breast, lung, and skin cancer. In some of these tissues, subsets of cells in the corresponding normal tissue (i.e., duct/mucosa cells) stained positive for RPTPh.
RPTPB immunotoxin-mediated cell cytotoxicity. The critical criteria for selecting a lead antibody are the ability to bind native epitope, become internalized, and kill tumor cells. To show antibody-mediated receptor internalization, U87 cells were treated with anti-RPTPh ectodomain antibodies, and the internalization of the receptor-antibody complex was measured ( Fig. 2A) . U87 cells treated with anti-RPTPh antibody but not control IgG treated show a punctate staining pattern indicative of internalization.
To show immunotoxin-mediated cell killing, glioma cells are treated with RPTPh antibodies as well as positive control antibodies (anti-EGFR-528 and anti-CD71), with known ability to bind, internalize, and kill target cells. The negative controls included an isotype control antibody and media alone. Following primary antibody treatment, the cells are incubated with a saporin toxin-conjugated anti-mouse IgG antibody (MAB-ZAP). If the primary antibody recognizes its target and gets internalized, then the toxin-antibody complex is delivered and kills the cells. Figure  2B shows that the lead RPTPh antibodies (1B9G4, 7A9B5, and 7E4B11), as well as the positive control antibodies, effectively kill tumor cells when coupled to the anti-mouse IgG immunotoxin. The isotype control antibody was unable to bind and internalize and thus could not kill these cells. Because 7A9B5 and 7E4B11 seemed to work slightly better than 1B9G4 and their corresponding hybridoma lines are more productive, they were selected for further evaluation.
Purified RPTPh-7E4B11 and RPTPh-7A9B5 antibodies were directly conjugated to saporin and evaluated in cell culture for the ability to kill glioma cells. In this experiment, glioma cells are treated with these RPTPh immunotoxins as well as control immunotoxins. The negative controls included an IgG control antibody (Neg. Ctrl) or media alone (Vehicle). The positive control DAT-SAP antibody (Pos. Ctrl) targets the dopamine transporter expressed on astrocytoma cells. If the immunotoxin recognizes its target and gets internalized, then the toxin payload is delivered and kills the cells. Figure 2C shows that the immunotoxins 7A9B5-SAP and 7E4B11-SAP, as well as the positive control antibody, effectively kill tumor cells when directly coupled to the toxin. The isotype control antibody was unable to bind and internalize and thus could not kill these cells.
RPTPh has been shown to play a role in tumor cell invasion, migration, and adhesion (2) . However, to date, it is unclear if RPTPh activity promotes tumor growth. Using short interfering RNA to knock down RPTPh, we did not see an effect on U87 cell proliferation (data not shown). In addition, studies using pleiotrophin, one of RPTPh's ligands, failed to show a clear enhancement of cell proliferation (data not shown). In contrast, pleiotrophin does enhance colony formation in soft agar assays (5), supporting the notion that RPTPh may play a role in tumor growth in complex cellular systems. To better understand the role of RPTPh in tumor cell growth, we tested whether the lead RPTPh antibody, 7E4B11, could function as an unconjugated antibody to inhibit tumor cell growth. The 7E4B11 antibody (and other RPTPh antibodies) failed to inhibit U87 cell proliferation when simply grown in standard culture conditions over a number of days (data not shown). We then set out to test if 7E4B11 could inhibit or prevent colony formation in soft agar. U87 cells were seeded into soft agar, and then the cells were grown in the presence of test and control antibodies (Fig. 2D) . Control IgG1 antibody did not inhibit colony formation in soft agar. In contrast, the positive control EGFR antibody and 7E4B11 had fewer and smaller colonies. Therefore, 7E4B11 is able to modulate RPTPh function and thereby inhibit U87 tumor formation in soft agar.
In vivo efficacy of 7E4B11 immunotoxin. As part of the in vivo proof-of-concept studies for RPTPh targeted immunotoxin, we undertook U87 tumor growth delay studies using the 7E4B11 antibody. These studies are designed to determine the ability of 7E4B11 to target and delay tumor growth and are summarized in Table 3 . The immunotoxin consists of 7E4B11 directly linked to saporin (7E4B11-SAP).
U87 tumors were engrafted in Matrigel s.c., and treatments began when the tumors reached 140 mm 3 . The activities of 7E4B11-SAP were compared with that of vehicle (PBS) and nonspecific IgG1-SAP delivered i.t. Mice were euthanized when tumors reached the end-point volume (1,500 mm 3 ). Nontargeted IgG1-SAP treatments at 15 Ag/dose produced only 2% tumor growth delay (TGD). However, at 30 Ag/dose, IgG1-SAP produced 24% TGD. At 15 and 30 Ag/dose, 7E4B11-SAP produced 25% and 73% TGD, respectively, and were highly significant (P < 0.001; Fig. 3A ). All tumors reached the end-point volume by day 44. The median time to end point (TTE) of PBS-treated mice was 18.6 days. Whereas the 7E4B11-SAP (30 Ag/dose) treated mice had a TTE of 32.1 days (Fig. 3B) . These results show that 7E4B11-SAP has significant antitumor activity.
We then set out to determine the antitumor activity of unconjugated 7E4B11 in the human U87 glioblastoma xenograft model. Nude mice received i.p. injections of 7E4B11, control IgG, or PBS twice weekly for 2 weeks. All treatments began on day 1 in groups of 10 mice bearing well-established (130 mm 3 ) U87 glioblastomas; i.p. 7E4B11 (20 Ag/dose) treatment produced 27% tumor growth delay (P < 0.05) relative to the vehicle, whereas the IgG treatment group did not show statistically significant antitumor activity. In addition, 7E4B11 treatment yielded two 60-day survivors with partial regression responses. The 7E4B11 unconjugated antibody was well tolerated, and no toxic deaths were recorded (data not shown).
The cross-reactivity of 7E4B11 to peripheral tissue, especially those tissues involved in absorption, secretion, and toxicity, is important to establish. Especially, if an antibody toxin conjugate is to be generated. To this end, we studied, colon, kidney, liver, small intestine, and stomach tissues for cross-reaction to 7E4B11 (Fig. 3C) . No cross-reactivity was seen in these tissues. The astrocytoma-positive control displays extensive staining, whereas the isotype-negative control IgG did not stain.
Discussion
Astrocytomas are the most common and often deadly form of brain tumor. RPTPh expression in astrocytomas has been described and correlates with increased malignancy (3). One approach for the treatment of astrocytoma is the delivery of therapeutic antibodies i.c. This avoids the difficulties in penetrating the blood-brain barrier and may be an effective way to target and destroy tumor cells that remain after surgical resection. RPTPh has many hallmark features of a functional tumor biomarker. RPTPh seems to be very CNS specific. This suggests the opportunity to target peripheral tumors for destruction while avoiding toxicity to normal tissue. In the case of astrocytoma/glioblastoma, RPTPh is overexpressed and could be an excellent biomarker and therapeutic target. Others and we have shown the overexpression of both long and short RPTPh isoforms in astrocytoma using functional genomics and immunohistochemistry (2-4). The role of short and long RPTPh in cell adhesion and migration suggests an important function in tumor cell biology (4) . Therefore, the development of RPTPh antibodies may prove useful for the treatment of astrocytoma and other cancers. RPTPh seems to be nonessential to normal tissues, as shown by the lack of phenotype of the knockout mouse (23) . These mice are normal except for sensitivity to EAE (murine multiple sclerosis model) and have impaired remyelination following insult (24) . In contrast, tumor cells seem to require RPTPh for adhesion, migration, and growth (2, 4, 25) . These observations would suggest that RPTPh can be safely targeted by therapeutic antibodies.
Because both long and short RPTPh are expressed in astrocytomas and facilitate tumor cell adhesion and migration, we developed antibodies to the ectodomain of RPTPh and characterized them for binding and efficacy in tumor cell killing. The entire ectodomain of short RPTPh was used to immunize mice and generate antibodies. Therefore, a better characterization of the antibody-binding sites and understanding of ligand-receptor interactions will be undertaken. We show that 7E4B11 and several other RPTPh antibodies have low nanomolar affinity. This seems to be adequate for in vivo efficacy. However, higher-affinity interactions could facilitate increased uptake of immunotoxin or enhance the presumed effects on signal transduction (altered adhesion, invasion, and growth).
The RPTPh antibodies described here are selective, have reasonable affinities, bind native surface RPTPh, and get internalized (either actively or passively). RPTPh is probably continuously may be the one rapidly internalized. This is in contrast to the models of antibody-mediated internalization suggested for receptor tyrosine kinases. Some EGFR antibodies bind and activate this receptor and thereby trigger internalization (1) .
RPTPh seems to be important for maximum tumor growth in situations of contact independence or in complex cellular environments. RPTPh binds to matrix proteins, such as NCAMs and tenascin (15) (16) (17) . These interaction may be necessary for tumor growth or survival (resistance to anoikis) in in vivo settings. The complex nature of RPTPh biology is consistent with the studies of pleiotrophin and the protumor role it plays. Wherein, pleiotrophin promotes colony formation and in vivo tumor growth but lacks direct cell proliferative activity in cell culture models (5, 7). In our hand, the RPTPh antibody-7E4B11 seems to slow tumor growth in soft agar and tumor growth in vivo.
The ability of RPTPh antibodies to target and kill U87 tumors provides proof of concept for the development of better RPTPh immunotoxins. Currently, several small molecular peptide and protein toxins are being evaluated for efficacy as antibody conjugates (26, 27) . Ideally, the antibody-toxin conjugate should be selective to tumor cells and have a linker that is cleaved inside the cell and a toxin that is potent. These characteristics ensure that only tumors get killed and normal tissues are spared. Saporin is a ribosomal inhibiting protein toxin and, although useful for research studies, has not proved itself for clinical application, due to its size and immunogenecity (28) . Immunotoxins must not be immunogenic (as is often the case for protein toxins) and should retain the desired characteristics of the antibody (stability, affinity, selectivity, and function). Systemic delivery of an immunotoxin is risky if the antibody is not sufficiently targeted or if the toxin has undesired side effects. A ''naked, '' unconjugated antibody is ideal, but many of the same hurdles still need to be overcome (29) . The naked antibody must be highly tumor selective and able to modulate its target such that tumor cells die and normal cells are not affected. In many cases, this can be a ''tall order'' and unwanted side effects due to dysregulation of signaling pathways can be just as devastating as toxin-mediated side effects. This is because many antibody targets play important roles in normal cellular functions. In many ways, RPTPh is an ideal target (tumor-selective expression, functional relevance) and is nonessential for normal tissues. The further study of RPTPh and its antibodies may facilitate development of therapeutics for the treatment of cancer.
